Clinical trials: Stage I Liver Cancer
Advanced Hepatocellular Carcinoma (HCC)
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
This study consists of two parts: Phase I is a dose escalation study to determine the Recommended Phase II Dose (RP2D) of MGD013 monotherapy and that of MGD013 when in combination with Brivanib Alaninate (ZL-2301) in subjects…
- Trial name
- NCT04212221
- Testing
- MGD013 monotherapy, MGD013 in combination with Brivanib Alaninate
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Hepatocellular Carcinoma
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
The purpose of this study is to characterize the baseline variability of a panel of tissue (tumor and adjacent) and blood-based biomarkers obtained from participants with hepatocellular carcinoma (HCC).
- Trial name
- NCT01521780
- Testing
- MRI, Pathology, Blood Samples
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Hepatocellular
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
Liver cancer is a good target for anti-angiogenic treatments such as pazopanib. The effect of pazopanib in patients with liver cancer are unknown.
- Trial name
- NCT00370513
- Testing
- pazopanib
- Where
- 3 sites in United States, Hong Kong and 1 more
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer, Gastric Cancer
TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of orally administered TT-4 in subjects with advanced selected solid tumors.
- Conditions
- Colorectal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Pancreatic Cancer
- Trial name
- NCT04976660
- Testing
- TT-4
- Sponsor
- Tarus Therapeutics, Inc.
Colon Cancer Liver Metastasis
Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer
The purpose of this study is to test an experimental anti-cancer immunotherapy called NKR-2 (modified T cells), to treat colorectal cancer with unresectable liver metastases.
- Trial name
- LINK (NCT03370198)
- Testing
- NKR-2 cells
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Celyad Oncology SA
Breast Cancer, Glioma
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast…
- Conditions
- Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00909558
- Testing
- Autologous Natural Killer / Natural Killer T Cell Immunotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Envita Medical Center, Inc.
Advanced Solid Tumor, Lung Cancer
A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.
This is a multicenter, open-label study conducted in 3 phases: Dose escalation stage: The stage contain 4 cohorts, each cohort divided into 2 groups （group A, single dose and Group B, multiple dose）.Dose escalation will use a 3+3…
- Conditions
- Advanced Solid Tumor, Lung Cancer, Liver Cancer, Lymphoma
- Trial name
- NCT05598268
- Testing
- T3011
- Where
- 7 sites in China
- Volunteers
- 74 people
- Sponsor
- ImmVira Pharma Co. Ltd
Solid Tumor Malignancies, Cancer, Solid Cancers
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with…
- Conditions
- Solid Tumor Malignancies, Cancer, Solid Cancers, Solid Tumor Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT06883539
- Testing
- LXP1788 is administered intravenously via Port-A
- Where
- 2 sites in Taiwan
- Volunteers
- 24 people
- Sponsor
- LaunXP Biomedical Co., Ltd.
Colon Cancer Liver Metastasis
Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases
SHRINK (Standard cHemotherapy Regimen and Immunotherapy with NKR-2) is an open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells administered concurrently with a…
- Trial name
- SHRINK (NCT03310008)
- Testing
- NKR-2 cells
- Where
- 4 sites in Belgium
- Volunteers
- 36 people
- Sponsor
- Celyad Oncology SA
Hepatocellular Carcinoma
Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)
The purpose of this study is to assess efficacy and safety in combination of resminostat and sorafenib in Asian patients with advanced HCC previously untreated with systemic chemotherapy.
- Trial name
- NCT02400788
- Testing
- Resminostat, Sorafenib
- Where
- 12 sites in Japan, South Korea
- Volunteers
- 179 people
- Sponsor
- Yakult Honsha Co., LTD
Hepatocellular Carcinoma, Liver Cancer
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
This is a open-label, dose escalation, multi-center, Phase I / Phase II study to assess the safety of an autologous T-cell product (ET140202) in adult subjects with advanced Alpha-fetoprotein (AFP) positive/Human Leukocyte…
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Metastatic Liver Cancer
- Trial name
- ET-109 (NCT03998033)
- Testing
- ET140202 autologous T cell product
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Eureka Therapeutics Inc.
Carcinoma, Hepatocellular, Biliary Tract Cancer
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Phase I study of RO7119929 given orally to participants with unresectable advanced or metastatic primary liver cancers and other solid tumors with predominant liver involvement.
- Conditions
- Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer, Liver Metastases
- Trial name
- NCT04338685
- Testing
- RO7119929, Tocilizumab
- Where
- 10 sites in United States, Denmark and 4 more
- Volunteers
- 55 people
- Sponsor
- Hoffmann-La Roche
Melanoma, Liver Cancer
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer
The main purpose of this study is to study the safety of OrienX010 in the treatment of kinds of solid tumors such as melanoma,liver cancer,pancreatic cancer and lung cancer.
- Conditions
- Melanoma, Liver Cancer, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT01935453
- Testing
- Recombinant hGM-CSF Herpes Simplex Virus Injection
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- OrienGene Biotechnology Ltd.
Hepatocellular Carcinoma
Chimeric Antigen Receptor T Cells Targeting Glypican-3
A Phase I Clinical Study of Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CAR-GPC3 T Cells) in Patients with Advanced Hepatocellular Carcinoma
- Trial name
- NCT03884751
- Testing
- CAR-GPC3 T Cells
- Where
- 6 sites in China
- Volunteers
- 9 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Advanced or Metastatic HCC
A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
This phase I trial is studying the safety and best dose of GC33 in patients with advanced or metastatic liver cancer.
- Trial name
- NCT00746317
- Testing
- GC33
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Chugai Pharmaceutical
Liver Cancer
NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers
The purpose of this Phase I / II study is to evaluate the safety and preliminary efficacy of NBTXR3 nanoparticles given by intralesional (IL) or intraarterial (IA) injection and activated by Stereotactic Body Radiation Therapy in…
- Trial name
- NCT02721056
- Testing
- NBTXR3, IL or IA injection + SBRT
- Where
- 7 sites in France
- Volunteers
- 23 people
- Sponsor
- Nanobiotix
Locally Advanced/Metastatic Liver Cancer
Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer
This is an open, single-arm, investigator-initiated Phase I clinical trial to evaluate the safety, tolerability, and initial efficacy of BST02 injection in patients with locally advanced / metastatic liver cancer.
- Trial name
- NCT06173726
- Testing
- BST02 Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- BioSyngen Pte Ltd
Breast Cancer, Head and Neck Squamous Cell Carcinoma
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Many patients have cancers that have increased activity of a protein called STAT3 that contributes critically to the development and growth of their cancer.
- Conditions
- Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer
- Trial name
- NCT03195699
- Testing
- TTI-101
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Ewings Sarcoma, Non Small Cell Lung Cancer
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Autologous Vigil™ vaccine expresses rhGMCSF and bi-shRNAfurin from the Vigil™ plasmid. The GMCSF protein is a potent stimulator of the immune system, recruiting immune effectors to the site of intradermal injection and promoting…
- Conditions
- Ewings Sarcoma, Non Small Cell Lung Cancer, Liver Cancer
- Trial name
- NCT01061840
- Testing
- Vigil™
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Gradalis, Inc.
Hepatocellular Carcinoma
Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma
The primary objective of this study is to answer the question "Is it possible to inject the COMBIG-DC vaccine in a hepatic tumor without getting unacceptable side effects"?
- Trial name
- NCT01974661
- Testing
- COMBIG-DC (ilixadencel)
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Mendus